NEW YORK – Biofidelity and CellCarta said Thursday that they have formed a strategic partnership to use Biofidelity's lung cancer assay in clinical trials worldwide.
Under the agreement, Canadian global research contract organization CellCarta will validate the Aspyre Lung assay first in its European and then in its US-based labs. The Montreal-based company will have nonexclusive rights to use Aspyre Lung globally in clinical trials.
Financial details of the agreement were not disclosed.
"CellCarta offers an extensive portfolio of biomarker testing services and tailored solutions for the pharmaceutical and biotech industry," CellCarta CEO Dusty Tenney said in a statement. "The addition of Aspyre Lung to our capabilities marks an advancement in our mission to propel precision medicine with specialized laboratory services."
Aspyre Lung is a pyrophosphorolysis-based lung cancer mutation detection assay that targets 111 mutations in 11 genes of relevance to non-small cell lung carcinoma.
A year ago, Cambridge, UK-based Biofidelity partnered with Fidelis to supply the assay to Department of Veterans Affairs medical centers and active-duty military installations across the US.